Preliminary results in secondary acute non-lymphocytic leukemia (ANLL) treated with Idarubicin.
The results of Idarubicin treatment in patients with secondary acute non-lymphocytic leukemia are presented: 7 courses have been performed in 6 patients and 4 complete remissions have been induced in three of them. Tolerance was excellent and no cardiotoxicity was observed. However, remissions were short and combination therapy is suggested.